Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology

用于“See”的三峰聚合物胶束

基本信息

  • 批准号:
    8175145
  • 负责人:
  • 金额:
    $ 14.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-07 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The major goal of surgical oncology is the complete resection of tumors with adequate tumor-free margins and minimal surgical morbidity, noting that surgery cures about 45% of patients, whereas chemotherapy and radiation cure only 5% of patients. In lung, breast, prostate, colon, and pancreatic cancers, a complete resection of tumors has a 3- to 5-fold increase in survival over partial or incomplete surgical resection. However, the intraoperative assessment of tumor margins is merely based on palpation and visual inspection, resulting frequently in incomplete tumor resection (R1 resections). The goal is to develop nanotechnology for "see and treat" modalities in surgical oncology, enabled by polymeric micelles that emit tissue penetrating near-infrared light for delineation of tumor margins and surgical guidance; generate singlet oxygen upon intra- operative photodynamic therapy (PDT); and enhance cancer cell apoptosis by the co-delivery of gossypol, a natural BH3 mimetic that inhibits anti-apoptotic Bcl-2 proteins: Bcl-2, Bcl-xL, and Mcl-1. We have proven that poly(ethylene glycol)-block-poly(e-caprolactone) (PEG-b-PCL) assembles into nanoparticles that entrain a near-infrared dye (DiR), a photosensitizer (mTHPP), and gossypol, forming micelles that are 100 nm in diameter and slowly release all 3 components over 24 hrs. We hypothesize that PEG-b-PCL micelles filled with DiR, mTHPP, and gossypol will accumulate at solid tumors via the enhanced permeability and retention effect and "light up" tumor margins, enabling surgical guidance, more complete surgical resection, and lower tumor reoccurrence. We hypothesize that laser light delivered to the "lit up" region of the tumor bed (intraoperative PDT) will generate singlet oxygen that kills tumor cells, especially in concert with co-delivered gossypol. Specific Aims: (1) To assess the stability, generation of singlet oxygen, and tumor targeting of PEG-b-PCL micelles filled with DiR, mTHPP, and gossypol by in vitro physicochemical and photophysical studies and in vivo experiments: whole body optical imaging of DiR and mTHPP and a pharmacokinetics study on gossypol. (2). To assess tumor reoccurrence after surgical guidance by PEG-b-PCL micelles filled with DiR and surgical resection of tumors and after surgical resection of tumors alone as a positive control. (3). To assess tumor reoccurrence after surgical resection and intraoperative PDT with PEG-b-PCL micelles filled with mTHPP, with or without co-incorporated gossypol. (4). To assess tumor reoccurrence after optical imaging of DiR, surgical resection, and intraoperative PDT with mTHPP and gossypol (tri-modal therapy). Advances in integrated optical imaging and therapeutic capability of biocompatible PEG-b-PCL micelles will enable tenable nano-technology applications in surgical oncology and rapid translation into clinical trials. PUBLIC HEALTH RELEVANCE: The goal is to develop a unique tri-functional nanocarrier for surgical oncology that can deliver near-infrared dye, photosensitizer, and gossypol together into solid tumors for intraoperative optical imaging of solid tumors and light-activated cancer cell killing. In a mouse model of neuroblastoma, we will test whether surgical guidance, surgical resection, and intraoperative light-activated cancer cell killing will maximize tumor killing, minimize collateral damage, and prolong survival.
描述(申请人提供):外科肿瘤学的主要目标是完全切除肿瘤,具有足够的无肿瘤边缘和最低的手术并发症,并指出手术可治愈约45%的患者,而化疗和放射治疗仅能治愈5%的患者。在肺癌、乳腺癌、前列腺癌、结肠癌和胰腺癌中,完全切除肿瘤的存活率是部分或不完全手术切除的3-5倍。然而,术中对肿瘤边缘的评估仅仅基于触诊和肉眼检查,经常导致肿瘤不完全切除(R1切除)。其目标是开发纳米技术,用于外科肿瘤学中的“看到并治疗”模式,通过聚合物胶束发射组织穿透近红外线来描绘肿瘤边缘和手术指导;在术中光动力疗法(PDT)中产生单线态氧;并通过共传递棉酚来促进癌细胞凋亡,棉酚是一种天然的BH3模拟物,可抑制抗凋亡的Bcl-2蛋白:bcl2、bclxl和mcl1。我们已经证明,聚乙二醇-嵌段-聚(e-己内酯)(PEG-b-PCL)组装成纳米颗粒,携带近红外染料(Dir)、光敏剂(MTHPP)和棉酚,形成直径100 nm的胶束,并在24小时内缓慢释放所有这三种成分。我们假设,填充了DIR、mTHPP和棉酚的聚乙二醇b-PCL胶束将通过增强的渗透性和滞留效应积聚在实体肿瘤处,并“照亮”肿瘤边缘,使手术指导、更彻底的手术切除和更低的肿瘤复发率成为可能。我们假设,传输到肿瘤床“亮”区域的激光(术中PDT)将产生杀死肿瘤细胞的单线态氧,特别是与联合传递的棉酚协同作用。具体目的:(1)通过体外物理化学和光物理研究以及体内实验:对dir、mTHPP和棉酚的全身光学成像和棉酚的药代动力学研究,评价填充dir、mTHPP和棉酚的聚乙二醇b-PCL胶束的稳定性、单线态氧的产生和肿瘤靶向性。(2)。评价用填充DIR的聚乙二醇b-PCL胶束引导手术和手术切除肿瘤后的肿瘤复发情况,以及作为阳性对照的肿瘤单纯手术切除后的肿瘤复发情况。(3)。目的:评估手术切除和术中PDT后使用填充mTHPP的聚乙二醇b-PCL胶束的肿瘤复发情况,以及是否有共掺棉酚。(4)。评估直肠癌光学成像、手术切除、术中光动力疗法联合mTHPP和棉酚(三联疗法)后肿瘤复发情况。生物相容的聚乙二醇b-PCL胶束的集成光学成像和治疗能力的进展将使纳米技术在外科肿瘤学中的应用和快速转化为临床试验成为可能。 公共卫生相关性:目标是开发一种独特的三功能纳米载体,用于外科肿瘤学,可以将近红外染料、光敏剂和棉酚一起输送到实体肿瘤中,用于术中实体肿瘤的光学成像和光激活的癌细胞杀伤。在神经母细胞瘤的小鼠模型中,我们将测试手术指导、手术切除和术中光激活的癌细胞杀伤是否能最大限度地杀灭肿瘤,最大限度地减少附带损害,并延长生存时间。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Glen S. Kwon其他文献

Polymeric micelle nanocarriers in cancer research
Polymeric Micelles for Multi-Drug Delivery in Cancer
  • DOI:
    10.1208/s12249-014-0251-3
  • 发表时间:
    2014-12-11
  • 期刊:
  • 影响因子:
    4.000
  • 作者:
    Hyunah Cho;Tsz Chung Lai;Keishiro Tomoda;Glen S. Kwon
  • 通讯作者:
    Glen S. Kwon
Soluble Self-Assembled Block Copolymers for Drug Delivery
  • DOI:
    10.1023/a:1011991617857
  • 发表时间:
    1999-01-01
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Glen S. Kwon;Teruo Okano
  • 通讯作者:
    Teruo Okano
Production of paclitaxel-loaded PEG-emb/em-PLA micelles using PEG for drug loading and freeze-drying
使用聚乙二醇进行药物负载和冷冻干燥来生产紫杉醇负载的聚乙二醇-乳化/包埋-聚乳酸微球
  • DOI:
    10.1016/j.jconrel.2022.08.032
  • 发表时间:
    2022-10-01
  • 期刊:
  • 影响因子:
    11.500
  • 作者:
    Morteza Rasoulianboroujeni;Lauren Repp;Hye Jin Lee;Glen S. Kwon
  • 通讯作者:
    Glen S. Kwon
Paclitaxel Prodrugs with Sustained Release and High Solubility in Poly(ethylene glycol)-b-poly(ε-caprolactone) Micelle Nanocarriers: Pharmacokinetic Disposition, Tolerability, and Cytotoxicity
  • DOI:
    10.1007/s11095-007-9451-9
  • 发表时间:
    2007-10-03
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    M. Laird Forrest;Jaime A. Yáñez;Connie M. Remsberg;Yusuke Ohgami;Glen S. Kwon;Neal M. Davies
  • 通讯作者:
    Neal M. Davies

Glen S. Kwon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Glen S. Kwon', 18)}}的其他基金

Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
  • 批准号:
    10409814
  • 财政年份:
    2021
  • 资助金额:
    $ 14.33万
  • 项目类别:
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
  • 批准号:
    10199263
  • 财政年份:
    2021
  • 资助金额:
    $ 14.33万
  • 项目类别:
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡(乳酸)n-前药纳米药物
  • 批准号:
    10371257
  • 财政年份:
    2021
  • 资助金额:
    $ 14.33万
  • 项目类别:
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡聚(乳酸)n-前药纳米药物
  • 批准号:
    10597075
  • 财政年份:
    2021
  • 资助金额:
    $ 14.33万
  • 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
  • 批准号:
    8497027
  • 财政年份:
    2013
  • 资助金额:
    $ 14.33万
  • 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
  • 批准号:
    8786047
  • 财政年份:
    2013
  • 资助金额:
    $ 14.33万
  • 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
  • 批准号:
    8605161
  • 财政年份:
    2013
  • 资助金额:
    $ 14.33万
  • 项目类别:
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
用于“See”的三峰聚合物胶束
  • 批准号:
    8298518
  • 财政年份:
    2011
  • 资助金额:
    $ 14.33万
  • 项目类别:
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY
用于药物输送的生物特异性聚合物酶缀合物
  • 批准号:
    6262537
  • 财政年份:
    2001
  • 资助金额:
    $ 14.33万
  • 项目类别:
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY
用于药物输送的生物特异性聚合物酶缀合物
  • 批准号:
    6489389
  • 财政年份:
    2001
  • 资助金额:
    $ 14.33万
  • 项目类别:

相似海外基金

Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
  • 批准号:
    10607815
  • 财政年份:
    2023
  • 资助金额:
    $ 14.33万
  • 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
  • 批准号:
    10723868
  • 财政年份:
    2023
  • 资助金额:
    $ 14.33万
  • 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
  • 批准号:
    10862033
  • 财政年份:
    2023
  • 资助金额:
    $ 14.33万
  • 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
  • 批准号:
    10622209
  • 财政年份:
    2023
  • 资助金额:
    $ 14.33万
  • 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
  • 批准号:
    22H03963
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
  • 批准号:
    10388929
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
  • 批准号:
    10356565
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10708827
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10538071
  • 财政年份:
    2022
  • 资助金额:
    $ 14.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了